FACTOR VIII & VON WILLEBRAND FACTOR COMPARISON CHART (PLASMA-DERIVED)

Product	Plasma source	Fractionation	Viral inactivation	Vial size	Storage	Availability
Humate-P Manufactured by CSL Behring	Canadian volunteer, non-remunerated blood donors	Multiple precipitation	1) cryoprecipitation; 2) Al(OH)3 adsorption, glycine precipitation, and NaCl precipitation; 3) pasteurization in aqueous solution at 60°C for 10 hours; 4) NaCl / glycine precipitation	250 IUs of FVIII (600 IUs of Ristocetin co-factor); 5 mL of diluent 500 IUs of FVIII (1,200 IUs of Ristocetin co-factor); 10 mL of diluent 1,000 IUs of FVIII (2,400 IUs of Ristocetin co-factor); 15 mL of diluent Mix2Vial™	Up to 25°C	Distributed in all provinces.

Comments

Indicated:

1) In adult patients for treatment and prevention of bleeding in hemophilia A;
2) In adult and pediatric patients for treatment of spontaneous and trauma-induced bleeding episodes in severe von Willebrand disease, and in mild and moderate von Willebrand disease where use of desmopressin is known or suspected to be inadequate;
3) To prevent excessive bleeding during and after surgery in adult and pediatric patients.

N.B. Results from the SIPPET study (N Engl J Med 2016; 374:2054-2064 May 26, 2016DOI: 10.1056/NEJMoa1516437) suggest that plasma-derived FVIII products containing von Willebrand factor, similar to Humate P and Wilate, may have a lower rate of inhibitor development in previously untreated patients (PUPs) compared to certain recombinant FVIII products.

Product	Plasma source	Fractionation	Viral inactivation	Vial size	Storage	Availability
Wilate Manufactured by Octapharma	USA: volunteer, remunerated plasmapheresis donors	Size exclusion high pressure liquid chromatography	Solvent detergent & dry heat (100°C, 120 minutes)	500 IUs of FVIII (500 IUs of VWF); 5 mL of diluent 1,000 IUs of FVIII (1,000 IUs of VWF); 10 mL of diluent Mix2Vial™	2-8°C, room temperature up to 25°C for up to 6 months, protect from light	Distributed in all provinces except Quebec.

Comments

Indicated for:

1) treatment and prophylaxis of bleeding in patients with hemophilia A and for the prevention and treatment of bleeding in minor surgical procedures;

2) treatment and prevention of bleeding episodes in all types of VWD in adult and pediatric patients where use of DDAVP is ineffective or contraindicated.

N.B. Results from the SIPPET study (N Engl J Med 2016; 374:2054-2064 May 26, 2016DOI: 10.1056/NEJMoa1516437) suggest that plasma-derived FVIII products containing von Willebrand factor, similar to Humate P and Wilate, may have a lower rate of inhibitor development in previously untreated patients (PUPs) compared to certain recombinant FVIII products.

Last revised – September 2, 2020